Zydus gets USFDA nod for schizophrenia treatment drug
Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market Clozapine tablets, used in the treatment of severe schizophrenia. The company has got final... Zydus gets tentative US FDA nod to sell pregabalin for seizures, pain
The drug will be produced at the group's formulations manufacturing facility in Moraiya, Ahmedabad Zydus gets USFDA nod for seizures, migraine drug; shares down 0.6%
Zydus Cadila has received final approval from the US health regulator to market topiramate extended release capsules used for the treatment of seizures and migraine. The company has received... Zydus' oral small molecule named Desidustat by WHO
Drug firm Zydus Cadila today said its oral anaemia developmental candidate, ZYAN1, has been named Desidustat by the World Health Organisation (WHO) INN Committee. The International Non-proprietary... Unaudited Financial Results For The Quarter / Half Year Ended On 30.09.2017
Unaudited Financial Results for the quarter / half year ended on 30.09.2017 along with limited review report [standalone and consolidated] and press release. Zydus gets regulatory nod to market Lipaglyn in Mexico
Zydus Cadila has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in patients with diabetes. The company... Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a teleconference call at 5.00 p.m. on Monday, November 13, 2017 for Q2 FY 18 post results Q&A; session. Notice For The Meeting Of Board Of Directors / Closure Of Trading Window
We hereby inform that a meeting of the Board of Directors of the Company will be held on Monday, November 13, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed... Notice For The Meeting Of Board Of Directors / Closure Of Trading Window
We inform that a meeting of the Board of Directors of the Company will be held on Monday, November 13, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from... Certificate Under Regulation 40 (10) Of SEBI (LODR) Regulations, 2015
The certificate as required under Regulation 40[10] of the SEBI [Listing Obligations and Disclosure Requirements], Regulations, 2017 for the half year - April 1, 2017 to September 30, 2017, issued by Hitesh Buch & Associates, Practicing Company Secretaries.